Protecting the world against pertussis and other global re-emerging diseases

BioNet is a vaccine manufacturer specializing in the development of recombinant and mRNA vaccines against respiratory diseases and other global public health threats. BioNet has a strong track record with development and biomanufacturing, having advanced many proprietary recombinant pertussis vaccines from early R&D to licensure. It currently markets multiple vaccines through its established commercial network. BioNet has been rapidly expanding its operations across all continents.

Download PDF
Bionet workers test and inspect a vial packing machine where mRNA COVID19 vaccines will be produced after clinical trials are completed, at a factory in Ayutthaya, Thailand on 7, October, 2021. Bionet is a vaccine manufacturer that is producing Thailand’s mRNA COVID19 vaccine that was developed by a team from Chulalongkorn University.

State-of-the-art manufacturing capabilities

BioNet commits to develop and manufacture innovative high-quality vaccines that comply with applicable regulatory requirements. BioNet aims to integrate quality beyond compliance in both products and processes through continuous improvement of our quality system.

Our vaccines are manufactured in accordance to Good Manufacturing Practices (GMP) PIC/S standards, and tested at each manufacturing step as per pharmacopeia requirements in our own quality control and testing facilities.

BioNet Key Facts

3

licensed
recombinant pertussis vaccines

200+

qualified and passionate individuals fueling vaccine innovation

25+

years’ experience
in vaccines

20

clinical trials
conducted

10+

mRNA
candidates

BioNet Wins BARDA Patch Forward Prize for Microneedle mRNA Vaccine Innovation

Lyon, France & Bangkok, Thailand – January 17, 2025 – BioNet, a global leader in vaccine innovation, proudly announces its selection as a Concept Stage winner in the prestigious United States Biomedical Advanced Research and Development Authority (BARDA) Patch Forward Prize. Achieved in collaboration with LTS Lohmann Therapie-Systeme AG, this recognition underscores BioNet’s contributions to mRNA vaccine technologies and their transformative potential to improve global health.

Read more

LTS and BioNet Win U.S. BARDA Patch Forward Prize Competition

Andernach – LTS, a leading pharmaceutical technology company, and BioNet, a biotech manufacturer specializing in genetically engineered vaccines, announced today their selection as a Concept Stage winner of the #PatchForwardPrize, a $50 million challenge by BARDA to advance microneedle patch-based RNA vaccine technologies.
Read more >

BARDA announces $8 million in awards to advance microneedle patch-based RNA vaccine development as part of the Patch Forward Prize

Today, the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR), announced four winners of the Concept Stage of the Patch Forward Prize. Read more >

Today’s Biotech Discoveries